Skip to content

Medical emergency? What to do

Maternal mood disorder and newborn neurobehavior

3-RXPublished November 26, 20133 min read

Key points

  • A great number of women experience depression or anxiety while pregnant, and exposure of the fetus to these maternal mood disorders may lead to long-term emotional and behavioral problems in the offspring.
  • Exposure to maternal mood disorder in utero may program infant neurobehavior via DNA methylation of the glucocorticoid receptor (NR3C1) and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2), two placental genes that have been implicated in perturbations of the hypothalamic pituitary adrenocortical (HPA) axis.
  • The researchers found support for the idea that transmission of risk for poor neurodevelopmental outcomes may actually occur prenatally.
  • Many studies have shown that the fetal environment has a strong influence on offspring neurobehavioral outcomes by altering the developing brain, although the exact mechanisms by which this occurs are not completely understood.

A great number of women experience depression or anxiety while pregnant, and exposure of the fetus to these maternal mood disorders may lead to long-term emotional and behavioral problems in the offspring. Many studies have shown that the fetal environment has a strong influence on offspring neurobehavioral outcomes by altering the developing brain, although the exact mechanisms by which this occurs are not completely understood.

Researchers from the Brown Center for the Study of Children at Risk, Women and Infants Hospital of Rhode Island, Brown University, in Providence, RI, have now tested the influence of maternal depression and/or anxiety during pregnancy on newborn neurobehavior by specifically looking at epigenetic changes (modifications on the DNA that are different from changes in DNA sequence) in two genes expressed in the placenta that have been previously implicated in perturbations of the HPA axis (a system that controls reactions to stress and regulates many body processes).

In a study published in the December 2013 issue of Epigenetics, the authors report that specific adjustments that occur in the fetus (more specifically in the regulation of gene expression) in response to cues from the intrauterine environment, in this case an increased exposure to maternal cortisol, may lead to poor neurodevelopmental outcomes.

The researchers found support for the idea that transmission of risk for poor neurodevelopmental outcomes may actually occur prenatally. This research highlights the importance of treating maternal prenatal depression and anxiety so that risk for poor newborn behavioral outcomes is mitigated.

###

Exposure to maternal mood disorder in utero may program infant neurobehavior via DNA methylation of the glucocorticoid receptor (NR3C1) and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2), two placental genes that have been implicated in perturbations of the hypothalamic pituitary adrenocortical (HPA) axis. We tested the relations among prenatal exposure to maternal depression or anxiety, methylation of exon 1F of NR3C1 and 11β-HSD-2, and newborn neurobehavior. Controlling for relevant covariates, infants whose mothers reported depression during pregnancy and showed greater methylation of placental NR3C1 CpG2 had poorer self-regulation, more hypotonia, and more lethargy than infants whose mothers did not report depression. On the other hand, infants whose mothers reported anxiety during pregnancy and showed greater methylation of placental 11β-HSD-2 CpG4 were more hypotonic compared with infants of mothers who did not report anxiety during pregnancy. Our results support the fetal programming hypothesis and suggest that fetal adjustments to cues from the intrauterine environment, in this case an environment that could be characterized by increased exposure to maternal cortisol, may lead to poor neurodevelopmental outcomes.

###

Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.